Humanized mice|BioMice｜Biocytogen

Please enter keyword

OK

Please enter keyword

OK

Gene Editing

By species

By technologies

By strategies

Animal & Cell Models

Humanized animal models

Immune checkpoint humanized mice

Cytokine humanized mice

GPCR humanized mice

Other humanized mice

KO mouse models

Drug target knockout mice

Other knockout mice

Tool mice

Other tool mice

Immunodeficient mice/rats

B-NDG series immunodeficient mice

Other immunodeficient mice/rats

Cell lines

Humanized cell lines

Mouse derived cell lines

Reporter cell lines

Other cell lines

Aged mice

Disease mouse models

Oncology Disease

Autoimmune Disease

Nervous System Disease

Metabolic Disease

Orthopedic Disease

Ophthalmic Disease

Cardiovascular diseases

Urinary System Disease

Surgical disease

Pharmacology Services

Therapeutic area

Metabolic diseases

Autoimmune diseases

Inflammatory diseases

Types of services

In vivo pharmacology

Ex vivo pharmacology

In vitro pharmacology

Pharmacokinetics (PK) assays

Pathological/Toxicological assays

Model/method development

Integrated solution

Molecule type

Peptide/protein

Technology

Other Services

Microbial detection

Animal Breeding

Animal Cryopreservation

Animal Rederivation

Resources & Activities

Technical support

News & events

About Us

Biocytogen animal center

Certifications

Join us

Contact us

Biocytogen

English|Chinese

English

Chinese

Resources&Activities

Technical support

Publications

Technical Q & A

Humanized mice

B-NDG mice

Others

Two novel human anti-CD25 antibodies with antitumor activity inversely related to their affinity and in vitro activity.

Used in this study: B-hIL2RA mice. Part Author's Institute: Shandong Luye Pharmaceutical Co., Ltd.

BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) induces tumor localized CD137 agonism

Used in this study: B-hTNFRS-F9, B-h4-1BB mice. Part Author's Institute: Bicycle Therapeutics.

Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity.

Used in this study: B-hPD-1/h4-1BB mice

Discovery of a novel anti PD-L1 X TIGIT bispecific antibody for the treatment of solid tumors.

Used in this study: B-hTIGIT mice, B-hPD-L1/hTIGIT mice. Part Author's Institute: Nanjing Sanhome Pharmaceutical Co., Ltd.

Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer.

Used in this study: B-h4-1BB, B-hPD-L1/h4-1BB mice

Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade

Used in this study: B-hPD-L1/h4-1BB mice. Part Author's Institute: ABL Bio Inc.

1 2 3 4 5 6 … 8

Technical support

News&events

Quality Assurance

Microbial detection

Animal health report

Genetic background detection

About us

+86-10-56967680

info@bbctg.com.cn

Copyright © 2024 BioMice. All Rights Reserved Powered by Fractal-technology